Pragmatic Target Discovery From Novel Gene to Functionally Defined Drug Target: The Interleukin-1 Story
The pro-inflammatory cytokine interleukin-1 (IL-1) has been proposed as a mediator of the acute neurodegenerative changes that occur following stroke. This is based largely on experimental studies in rodents, in particular the marked reduction in ischemic cell death seen when IL-1 receptor antagonist (IL-1ra) is administered. Mechanisms of IL-1 action remain largely unknown, but they may involve complex effects on many cells including microglia, astrocytes, neurons, and endothelial cells. In light of this, IL-1ra is currently under consideration as a potential treatment for stroke and other neurodegenerative conditions.
- Why Cannot a Rodent Be More Like a Man A Clinical Perspective
- Cocaine Self-Administration in Rats: Hold-Down Procedures
- Characterization of Voltage-Sensitive Dyes in Living Cells Using Two-Photon Excitation
- A Gi RNA-Antisense Expression Strategy to Investigate Coupling of Peptide YY/Neuropeptide Y Receptor to Gi
- Structure-Activity Relationships at the Benzodiazepine Receptor
- Biochemical Approaches to the Study of Peptide Actions
- Whole-Cell Voltage Clamp on Skeletal Muscle Fibers With the Silicone-Clamp Technique
- Enzymes of the Pyruvate Dehydrogenase Complex of Mammalian Brain
- Immunohistochemical Detection of Endothelial Proteins
- Assay of Arachidonic Acid Release Coupled to α1- and α2-Adrenergic Receptors